Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphangiogenesis | 8 | 2022 | 174 | 2.210 |
Why?
|
Neovascularization, Pathologic | 29 | 2018 | 2638 | 2.120 |
Why?
|
Neuropilin-2 | 5 | 2022 | 54 | 1.420 |
Why?
|
Neuropilin-1 | 6 | 2014 | 90 | 1.300 |
Why?
|
Neoplasm Metastasis | 19 | 2021 | 4851 | 1.200 |
Why?
|
Neuropilins | 5 | 2014 | 12 | 1.180 |
Why?
|
Lymphatic Vessels | 6 | 2023 | 353 | 0.910 |
Why?
|
Vascular Endothelial Growth Factor A | 16 | 2021 | 3511 | 0.880 |
Why?
|
Neovascularization, Physiologic | 6 | 2018 | 1351 | 0.800 |
Why?
|
Epidermis | 4 | 2014 | 528 | 0.700 |
Why?
|
Lymphatic Metastasis | 7 | 2015 | 2924 | 0.680 |
Why?
|
Interferon-beta | 9 | 2003 | 324 | 0.640 |
Why?
|
Endothelial Cells | 15 | 2023 | 3486 | 0.630 |
Why?
|
Semaphorin-3A | 2 | 2014 | 39 | 0.570 |
Why?
|
Eicosanoids | 5 | 2021 | 279 | 0.560 |
Why?
|
Lymphatic System | 2 | 2014 | 252 | 0.550 |
Why?
|
Nerve Tissue Proteins | 7 | 2019 | 4463 | 0.540 |
Why?
|
Receptors, Neurokinin-1 | 1 | 2016 | 129 | 0.530 |
Why?
|
Angiogenesis Inhibitors | 5 | 2016 | 2038 | 0.490 |
Why?
|
Lymphedema | 2 | 2023 | 534 | 0.490 |
Why?
|
Epithelial-Mesenchymal Transition | 3 | 2015 | 713 | 0.480 |
Why?
|
Muscle, Smooth | 2 | 2022 | 934 | 0.470 |
Why?
|
Neoplasms | 21 | 2024 | 21696 | 0.470 |
Why?
|
Cell Movement | 13 | 2020 | 5218 | 0.470 |
Why?
|
Epoxide Hydrolases | 5 | 2021 | 122 | 0.460 |
Why?
|
Muscle Contraction | 2 | 2022 | 1235 | 0.440 |
Why?
|
Liver Regeneration | 1 | 2014 | 210 | 0.440 |
Why?
|
Thrombospondin 1 | 4 | 2022 | 250 | 0.430 |
Why?
|
Semaphorins | 3 | 2009 | 101 | 0.430 |
Why?
|
Adaptor Proteins, Vesicular Transport | 3 | 2021 | 315 | 0.430 |
Why?
|
Microcirculation | 3 | 2021 | 1287 | 0.410 |
Why?
|
Regeneration | 2 | 2018 | 1485 | 0.410 |
Why?
|
Membrane Proteins | 7 | 2016 | 7882 | 0.400 |
Why?
|
Epithelium | 1 | 2016 | 1679 | 0.380 |
Why?
|
Capillary Permeability | 3 | 2016 | 798 | 0.370 |
Why?
|
Mouth Neoplasms | 1 | 2016 | 601 | 0.370 |
Why?
|
Cytoskeleton | 3 | 2012 | 1185 | 0.360 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2016 | 4034 | 0.360 |
Why?
|
Skin Neoplasms | 6 | 2016 | 5692 | 0.340 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 4 | 2018 | 547 | 0.340 |
Why?
|
Animals | 69 | 2023 | 168768 | 0.340 |
Why?
|
Mice | 55 | 2023 | 81201 | 0.340 |
Why?
|
Neoplasm Invasiveness | 5 | 2014 | 3616 | 0.310 |
Why?
|
rho-Associated Kinases | 2 | 2023 | 279 | 0.300 |
Why?
|
Neoplastic Stem Cells | 1 | 2015 | 1376 | 0.300 |
Why?
|
Wound Healing | 1 | 2018 | 2785 | 0.300 |
Why?
|
Interleukin-1beta | 1 | 2013 | 972 | 0.300 |
Why?
|
Neoplasms, Experimental | 5 | 2019 | 1276 | 0.300 |
Why?
|
Cell Line, Tumor | 23 | 2023 | 16690 | 0.290 |
Why?
|
Mice, Inbred BALB C | 9 | 2019 | 6386 | 0.290 |
Why?
|
Trachea | 1 | 2013 | 1076 | 0.290 |
Why?
|
Graves Ophthalmopathy | 2 | 2020 | 117 | 0.280 |
Why?
|
Receptors, Growth Factor | 1 | 2007 | 334 | 0.280 |
Why?
|
Urinary Bladder | 3 | 2020 | 1173 | 0.280 |
Why?
|
Cell Differentiation | 6 | 2016 | 11486 | 0.260 |
Why?
|
Mice, Transgenic | 10 | 2017 | 9735 | 0.260 |
Why?
|
Mice, Nude | 16 | 2014 | 3689 | 0.250 |
Why?
|
Proteoglycans | 4 | 2014 | 837 | 0.230 |
Why?
|
Docosahexaenoic Acids | 3 | 2019 | 875 | 0.230 |
Why?
|
Blotting, Northern | 4 | 2014 | 1581 | 0.230 |
Why?
|
Immunohistochemistry | 11 | 2017 | 11366 | 0.230 |
Why?
|
Colonic Neoplasms | 5 | 2023 | 2542 | 0.220 |
Why?
|
Cell Proliferation | 16 | 2021 | 10483 | 0.220 |
Why?
|
Recombinant Proteins | 7 | 2018 | 6621 | 0.220 |
Why?
|
Melanocytes | 3 | 2017 | 515 | 0.220 |
Why?
|
Blotting, Western | 4 | 2014 | 5181 | 0.210 |
Why?
|
Heparin | 2 | 2021 | 1637 | 0.210 |
Why?
|
Lung | 6 | 2021 | 9857 | 0.210 |
Why?
|
Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 41 | 0.200 |
Why?
|
Keratinocytes | 4 | 2014 | 799 | 0.200 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2014 | 336 | 0.200 |
Why?
|
Liver | 4 | 2023 | 7475 | 0.200 |
Why?
|
rhoA GTP-Binding Protein | 2 | 2012 | 241 | 0.200 |
Why?
|
Gastrointestinal Motility | 1 | 2022 | 225 | 0.190 |
Why?
|
Cytokines | 6 | 2023 | 7323 | 0.190 |
Why?
|
Mice, Inbred C57BL | 14 | 2021 | 21833 | 0.190 |
Why?
|
Oxazolone | 1 | 2020 | 60 | 0.190 |
Why?
|
Skin | 4 | 2005 | 4372 | 0.190 |
Why?
|
In Situ Hybridization | 4 | 2014 | 1950 | 0.180 |
Why?
|
Phenotype | 3 | 2015 | 16367 | 0.180 |
Why?
|
Cyclooxygenase 2 | 2 | 2020 | 612 | 0.180 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2021 | 137 | 0.170 |
Why?
|
Ketorolac | 1 | 2019 | 79 | 0.170 |
Why?
|
Humans | 72 | 2024 | 744366 | 0.170 |
Why?
|
Antineoplastic Agents | 7 | 2021 | 13693 | 0.170 |
Why?
|
Hemangioma, Capillary | 1 | 1999 | 61 | 0.160 |
Why?
|
Macrophages | 9 | 2021 | 5660 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2018 | 118 | 0.160 |
Why?
|
Pneumonectomy | 3 | 2021 | 1094 | 0.150 |
Why?
|
Signal Transduction | 10 | 2021 | 23404 | 0.150 |
Why?
|
Prostatic Neoplasms | 5 | 2014 | 11126 | 0.150 |
Why?
|
Neoplasm Proteins | 3 | 2021 | 3707 | 0.150 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 4751 | 0.150 |
Why?
|
Cytochrome P-450 Enzyme System | 2 | 2017 | 419 | 0.150 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2016 | 1677 | 0.150 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2017 | 81 | 0.140 |
Why?
|
Second Messenger Systems | 1 | 2017 | 206 | 0.140 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2019 | 320 | 0.140 |
Why?
|
Osteopontin | 1 | 2018 | 294 | 0.140 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2016 | 226 | 0.140 |
Why?
|
Chemokine CCL2 | 2 | 2019 | 619 | 0.140 |
Why?
|
Epithelial Cells | 2 | 2018 | 3690 | 0.140 |
Why?
|
Ubiquitination | 1 | 2021 | 1012 | 0.140 |
Why?
|
Saposins | 1 | 2016 | 27 | 0.140 |
Why?
|
Metabolic Diseases | 1 | 2022 | 658 | 0.140 |
Why?
|
Epoxy Compounds | 2 | 2013 | 136 | 0.130 |
Why?
|
Down-Regulation | 5 | 2012 | 3001 | 0.130 |
Why?
|
Fatty Acids | 1 | 2024 | 1809 | 0.130 |
Why?
|
Skin Pigmentation | 2 | 2014 | 282 | 0.130 |
Why?
|
Laminin | 2 | 2014 | 419 | 0.130 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 345 | 0.130 |
Why?
|
Keratin-1 | 1 | 2014 | 3 | 0.120 |
Why?
|
Ultraviolet Rays | 2 | 2002 | 1060 | 0.120 |
Why?
|
Retinal Neovascularization | 1 | 2017 | 244 | 0.120 |
Why?
|
Cell Separation | 1 | 2020 | 1751 | 0.120 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2016 | 664 | 0.120 |
Why?
|
Colon | 1 | 2022 | 1772 | 0.120 |
Why?
|
Choroidal Neovascularization | 1 | 2017 | 343 | 0.120 |
Why?
|
Phagocytosis | 4 | 2021 | 1539 | 0.120 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 808 | 0.120 |
Why?
|
Peptides, Cyclic | 1 | 2016 | 400 | 0.120 |
Why?
|
Collagen | 3 | 2014 | 2688 | 0.110 |
Why?
|
Cells, Cultured | 7 | 2017 | 19233 | 0.110 |
Why?
|
Fluorouracil | 1 | 2018 | 1619 | 0.110 |
Why?
|
Transplantation, Heterologous | 6 | 2014 | 2383 | 0.110 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2014 | 1085 | 0.110 |
Why?
|
Keratin-14 | 2 | 2005 | 57 | 0.110 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2017 | 1159 | 0.110 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1607 | 0.110 |
Why?
|
Cathepsin B | 1 | 2012 | 82 | 0.110 |
Why?
|
Extracellular Matrix Proteins | 2 | 2014 | 850 | 0.110 |
Why?
|
Tumor Microenvironment | 4 | 2022 | 3590 | 0.110 |
Why?
|
Disease Models, Animal | 11 | 2020 | 18034 | 0.110 |
Why?
|
Spinal Cord Injuries | 1 | 2020 | 931 | 0.100 |
Why?
|
Antigens, Ly | 1 | 2013 | 291 | 0.100 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2018 | 1115 | 0.100 |
Why?
|
Organ Specificity | 2 | 2012 | 2008 | 0.100 |
Why?
|
Blood Vessels | 2 | 2016 | 1125 | 0.100 |
Why?
|
Disease Progression | 6 | 2020 | 13286 | 0.100 |
Why?
|
Drug Combinations | 2 | 2014 | 1958 | 0.100 |
Why?
|
Models, Biological | 6 | 2018 | 9584 | 0.100 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2016 | 484 | 0.100 |
Why?
|
Integrin alphaVbeta3 | 1 | 2012 | 111 | 0.100 |
Why?
|
Cell Division | 7 | 2004 | 4569 | 0.100 |
Why?
|
Keratins | 2 | 2005 | 515 | 0.100 |
Why?
|
Transfection | 5 | 2008 | 5895 | 0.100 |
Why?
|
Macrophage-Activating Factors | 1 | 2010 | 21 | 0.100 |
Why?
|
Interferon-alpha | 3 | 2002 | 895 | 0.100 |
Why?
|
Cell Shape | 1 | 2012 | 375 | 0.100 |
Why?
|
Mice, Knockout | 8 | 2022 | 14561 | 0.100 |
Why?
|
Polyethylene Glycols | 2 | 2017 | 1182 | 0.090 |
Why?
|
Polyglycolic Acid | 1 | 2012 | 407 | 0.090 |
Why?
|
Sus scrofa | 1 | 2012 | 437 | 0.090 |
Why?
|
Organoplatinum Compounds | 1 | 2012 | 408 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4839 | 0.090 |
Why?
|
Doxorubicin | 1 | 2017 | 2234 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2013 | 8432 | 0.090 |
Why?
|
Mice, Inbred C3H | 4 | 1998 | 964 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2916 | 0.090 |
Why?
|
Prodrugs | 1 | 2012 | 268 | 0.090 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 514 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2251 | 0.090 |
Why?
|
Carcinoma in Situ | 1 | 2016 | 806 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3773 | 0.090 |
Why?
|
Hep G2 Cells | 2 | 2021 | 393 | 0.090 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4253 | 0.090 |
Why?
|
Vitamin D-Binding Protein | 1 | 2010 | 129 | 0.090 |
Why?
|
Nerve Growth Factors | 1 | 2012 | 574 | 0.090 |
Why?
|
Inflammation | 6 | 2020 | 10637 | 0.080 |
Why?
|
Epidermal Growth Factor | 3 | 2008 | 709 | 0.080 |
Why?
|
Cell Line | 5 | 2020 | 16000 | 0.080 |
Why?
|
Lipid Metabolism | 1 | 2017 | 1889 | 0.080 |
Why?
|
Cyclic AMP | 1 | 2012 | 1472 | 0.080 |
Why?
|
Osteolysis | 1 | 2010 | 270 | 0.080 |
Why?
|
Arteriovenous Malformations | 1 | 2011 | 396 | 0.080 |
Why?
|
Drug Discovery | 1 | 2016 | 1058 | 0.080 |
Why?
|
Lipocalins | 1 | 2009 | 170 | 0.080 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2012 | 687 | 0.080 |
Why?
|
Diabetic Retinopathy | 1 | 2017 | 1210 | 0.080 |
Why?
|
Tumor Cells, Cultured | 10 | 2018 | 6313 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2017 | 2259 | 0.080 |
Why?
|
Vascular Endothelial Growth Factors | 3 | 2016 | 772 | 0.080 |
Why?
|
Acute-Phase Proteins | 1 | 2009 | 262 | 0.080 |
Why?
|
Hyperplasia | 3 | 2003 | 1185 | 0.080 |
Why?
|
Fibroblast Growth Factor 2 | 3 | 1998 | 599 | 0.080 |
Why?
|
Male | 28 | 2021 | 350115 | 0.080 |
Why?
|
Cyclohexanes | 1 | 2008 | 152 | 0.080 |
Why?
|
Transcription, Genetic | 3 | 1998 | 7721 | 0.080 |
Why?
|
Atherosclerosis | 1 | 2023 | 3444 | 0.080 |
Why?
|
Melanoma | 7 | 2017 | 5511 | 0.070 |
Why?
|
Angiogenesis Inducing Agents | 3 | 2014 | 282 | 0.070 |
Why?
|
Aspirin | 1 | 2019 | 3283 | 0.070 |
Why?
|
Sesquiterpenes | 1 | 2008 | 177 | 0.070 |
Why?
|
Lactic Acid | 1 | 2012 | 1132 | 0.070 |
Why?
|
Endothelial Growth Factors | 2 | 2000 | 694 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4222 | 0.070 |
Why?
|
Apoptosis | 6 | 2020 | 9724 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 3873 | 0.070 |
Why?
|
Immunophilins | 1 | 2005 | 20 | 0.070 |
Why?
|
Female | 26 | 2021 | 380193 | 0.070 |
Why?
|
Allergy and Immunology | 1 | 2008 | 169 | 0.070 |
Why?
|
Lymphokines | 2 | 2000 | 949 | 0.070 |
Why?
|
Spheroids, Cellular | 1 | 2008 | 351 | 0.070 |
Why?
|
Retina | 1 | 2017 | 2616 | 0.070 |
Why?
|
Receptors, Notch | 1 | 2010 | 739 | 0.070 |
Why?
|
PPAR alpha | 1 | 2007 | 197 | 0.070 |
Why?
|
Base Sequence | 2 | 2014 | 12797 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2018 | 3554 | 0.060 |
Why?
|
Receptor, erbB-3 | 1 | 2006 | 142 | 0.060 |
Why?
|
Granulocytes | 1 | 2007 | 548 | 0.060 |
Why?
|
Cell Survival | 4 | 2020 | 5882 | 0.060 |
Why?
|
Fatty Acids, Unsaturated | 2 | 2019 | 546 | 0.060 |
Why?
|
Osteoblasts | 1 | 2010 | 1166 | 0.060 |
Why?
|
Immunoblotting | 1 | 2008 | 1683 | 0.060 |
Why?
|
Gene Deletion | 1 | 2012 | 2751 | 0.060 |
Why?
|
Endothelium, Vascular | 4 | 2013 | 4459 | 0.060 |
Why?
|
Genetic Vectors | 3 | 2005 | 3424 | 0.060 |
Why?
|
Graft Rejection | 1 | 2017 | 4397 | 0.060 |
Why?
|
In Situ Nick-End Labeling | 1 | 2004 | 644 | 0.060 |
Why?
|
Cell Death | 2 | 2021 | 1707 | 0.060 |
Why?
|
Molecular Sequence Data | 3 | 2014 | 18111 | 0.060 |
Why?
|
Cell Adhesion | 2 | 2013 | 3144 | 0.060 |
Why?
|
Intercellular Junctions | 1 | 2023 | 203 | 0.060 |
Why?
|
Trypsinogen | 1 | 2022 | 86 | 0.060 |
Why?
|
Intestinal Mucosa | 2 | 2012 | 3037 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6773 | 0.050 |
Why?
|
Intestines | 1 | 2012 | 1924 | 0.050 |
Why?
|
Thalidomide | 1 | 2008 | 890 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 2850 | 0.050 |
Why?
|
Carbachol | 1 | 2022 | 226 | 0.050 |
Why?
|
Biomimetics | 1 | 2023 | 172 | 0.050 |
Why?
|
Trypsin | 1 | 2022 | 511 | 0.050 |
Why?
|
History, 21st Century | 1 | 2008 | 1534 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10183 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2012 | 2917 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11718 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7798 | 0.050 |
Why?
|
Aflatoxin B1 | 1 | 2020 | 18 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9240 | 0.050 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2006 | 808 | 0.050 |
Why?
|
Neoplastic Processes | 1 | 2020 | 35 | 0.050 |
Why?
|
Nanoparticles | 1 | 2012 | 1905 | 0.050 |
Why?
|
Gene Silencing | 3 | 2012 | 1539 | 0.050 |
Why?
|
Endothelium | 2 | 2016 | 778 | 0.050 |
Why?
|
Neoplasm Transplantation | 4 | 2010 | 2086 | 0.050 |
Why?
|
Breast Neoplasms | 4 | 2011 | 20824 | 0.050 |
Why?
|
Melanoma, Experimental | 2 | 2017 | 561 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9274 | 0.040 |
Why?
|
Hematocrit | 1 | 2021 | 636 | 0.040 |
Why?
|
History, 20th Century | 1 | 2008 | 2740 | 0.040 |
Why?
|
Plasminogen Inactivators | 1 | 2019 | 38 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.040 |
Why?
|
Bone and Bones | 1 | 2010 | 2576 | 0.040 |
Why?
|
RNA, Messenger | 6 | 2017 | 13035 | 0.040 |
Why?
|
Models, Animal | 1 | 2006 | 2173 | 0.040 |
Why?
|
Mice, SCID | 3 | 2019 | 2716 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2021 | 2214 | 0.040 |
Why?
|
Surface-Active Agents | 1 | 2018 | 159 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3567 | 0.040 |
Why?
|
Oligonucleotide Probes | 1 | 1998 | 427 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2013 | 644 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2018 | 126 | 0.040 |
Why?
|
Carcinogens | 1 | 2020 | 466 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2020 | 5974 | 0.040 |
Why?
|
Prostaglandins | 1 | 2019 | 405 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2010 | 2530 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 661 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 816 | 0.040 |
Why?
|
beta Catenin | 1 | 2023 | 1059 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3751 | 0.040 |
Why?
|
Glioblastoma | 1 | 2012 | 3481 | 0.040 |
Why?
|
Hirudins | 1 | 2018 | 183 | 0.040 |
Why?
|
Platinum | 1 | 2019 | 233 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 2018 | 446 | 0.040 |
Why?
|
Transcription Factor AP-1 | 1 | 2018 | 317 | 0.040 |
Why?
|
Isometric Contraction | 1 | 2017 | 143 | 0.040 |
Why?
|
Fibrosis | 1 | 2023 | 2029 | 0.040 |
Why?
|
Phosphatidylserines | 1 | 2017 | 193 | 0.040 |
Why?
|
Amino Sugars | 1 | 1996 | 40 | 0.040 |
Why?
|
Cyclization | 1 | 2016 | 65 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2009 | 4554 | 0.030 |
Why?
|
Lipoxins | 1 | 2019 | 412 | 0.030 |
Why?
|
Fibrosarcoma | 1 | 1998 | 348 | 0.030 |
Why?
|
Glucosamine | 1 | 1996 | 132 | 0.030 |
Why?
|
Medical Oncology | 1 | 2008 | 2267 | 0.030 |
Why?
|
Perfusion | 1 | 2020 | 1360 | 0.030 |
Why?
|
Drug Design | 1 | 2021 | 1076 | 0.030 |
Why?
|
RNA Interference | 1 | 2004 | 2890 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2018 | 551 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 552 | 0.030 |
Why?
|
Cell Adhesion Molecules | 2 | 2013 | 1602 | 0.030 |
Why?
|
Retroviridae | 1 | 1998 | 914 | 0.030 |
Why?
|
Taxoids | 1 | 2019 | 666 | 0.030 |
Why?
|
Urodynamics | 1 | 2017 | 347 | 0.030 |
Why?
|
Cell Growth Processes | 2 | 2006 | 399 | 0.030 |
Why?
|
Endocytosis | 1 | 2020 | 985 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2725 | 0.030 |
Why?
|
Respiratory Mucosa | 1 | 1998 | 427 | 0.030 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2006 | 2249 | 0.030 |
Why?
|
Time Factors | 3 | 2004 | 40075 | 0.030 |
Why?
|
Mucous Membrane | 1 | 1998 | 673 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 1999 | 2505 | 0.030 |
Why?
|
Nitric Oxide Synthase | 1 | 1997 | 915 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 970 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2018 | 640 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2005 | 3024 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2018 | 1617 | 0.030 |
Why?
|
Staining and Labeling | 1 | 1998 | 1101 | 0.030 |
Why?
|
Pigmentation | 1 | 2014 | 148 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 553 | 0.030 |
Why?
|
Nanomedicine | 1 | 2017 | 304 | 0.030 |
Why?
|
Fibroblasts | 1 | 2004 | 4162 | 0.030 |
Why?
|
Keratin-18 | 1 | 2013 | 39 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2019 | 1085 | 0.030 |
Why?
|
Exercise Test | 1 | 2021 | 2073 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1862 | 0.030 |
Why?
|
Receptor, TIE-2 | 1 | 2013 | 178 | 0.030 |
Why?
|
Vimentin | 1 | 2013 | 262 | 0.030 |
Why?
|
Annexin A2 | 1 | 2012 | 44 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 1115 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1782 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3255 | 0.030 |
Why?
|
Bone Marrow Cells | 2 | 2013 | 2513 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2020 | 1741 | 0.030 |
Why?
|
Growth Substances | 2 | 2005 | 784 | 0.030 |
Why?
|
Tumor Burden | 1 | 2017 | 1915 | 0.030 |
Why?
|
Middle Aged | 5 | 2017 | 213390 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2000 | 2943 | 0.020 |
Why?
|
Oligonucleotides, Antisense | 1 | 2013 | 433 | 0.020 |
Why?
|
Antibodies | 1 | 1999 | 2460 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 2076 | 0.020 |
Why?
|
Kinetics | 1 | 1998 | 6476 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2006 | 12073 | 0.020 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 257 | 0.020 |
Why?
|
Carcinogenicity Tests | 2 | 2002 | 41 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1997 | 1434 | 0.020 |
Why?
|
Metabolomics | 1 | 2019 | 1485 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2012 | 963 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 623 | 0.020 |
Why?
|
Macular Degeneration | 1 | 2017 | 980 | 0.020 |
Why?
|
Amino Acids | 1 | 2016 | 1737 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 29786 | 0.020 |
Why?
|
Transcription Factors | 2 | 2009 | 12207 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2006 | 5534 | 0.020 |
Why?
|
ADAM Proteins | 1 | 2011 | 243 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 976 | 0.020 |
Why?
|
Heart | 1 | 2022 | 4464 | 0.020 |
Why?
|
Leukocytes | 1 | 2017 | 2045 | 0.020 |
Why?
|
Eye | 1 | 2013 | 729 | 0.020 |
Why?
|
Phosphorylation | 3 | 2008 | 8436 | 0.020 |
Why?
|
Cadherins | 1 | 2013 | 907 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1888 | 0.020 |
Why?
|
DNA, Complementary | 2 | 2004 | 2050 | 0.020 |
Why?
|
Nitric Oxide | 1 | 1997 | 2132 | 0.020 |
Why?
|
Tyrphostins | 1 | 2008 | 67 | 0.020 |
Why?
|
Cinnamates | 1 | 2008 | 60 | 0.020 |
Why?
|
Oligopeptides | 1 | 2013 | 1189 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3589 | 0.020 |
Why?
|
Lipids | 1 | 2019 | 3307 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2013 | 1157 | 0.020 |
Why?
|
Radiation Chimera | 1 | 2007 | 223 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3638 | 0.020 |
Why?
|
Lung Neoplasms | 4 | 2002 | 13104 | 0.020 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2007 | 114 | 0.020 |
Why?
|
Cloning, Molecular | 2 | 2004 | 4320 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2010 | 1341 | 0.020 |
Why?
|
Isoenzymes | 1 | 2011 | 1728 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6459 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 2891 | 0.020 |
Why?
|
NF-kappa B | 1 | 2014 | 2499 | 0.020 |
Why?
|
Calcium | 1 | 1999 | 5755 | 0.020 |
Why?
|
Mesoderm | 1 | 2009 | 686 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2018 | 5096 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1988 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2007 | 898 | 0.020 |
Why?
|
Protein Binding | 2 | 2012 | 9384 | 0.020 |
Why?
|
Oxygen | 1 | 2017 | 4189 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 625 | 0.020 |
Why?
|
Corneal Neovascularization | 1 | 2007 | 188 | 0.020 |
Why?
|
Actins | 1 | 2012 | 2121 | 0.020 |
Why?
|
Glucose | 1 | 2017 | 4398 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2009 | 577 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 2 | 1999 | 1369 | 0.020 |
Why?
|
Quantum Dots | 1 | 2006 | 172 | 0.020 |
Why?
|
Carcinoma | 1 | 1996 | 2375 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2016 | 3280 | 0.020 |
Why?
|
Reference Values | 1 | 2011 | 4982 | 0.010 |
Why?
|
Environmental Exposure | 1 | 1998 | 4232 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12788 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5263 | 0.010 |
Why?
|
Organ Culture Techniques | 1 | 2006 | 813 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2012 | 4208 | 0.010 |
Why?
|
Cell Membrane | 1 | 2012 | 3749 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6366 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 1 | 1997 | 3143 | 0.010 |
Why?
|
Ligands | 1 | 2009 | 3282 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2017 | 3338 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2017 | 57776 | 0.010 |
Why?
|
Receptors, Interferon | 1 | 2002 | 115 | 0.010 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2002 | 106 | 0.010 |
Why?
|
Quinazolines | 1 | 2008 | 1356 | 0.010 |
Why?
|
Adult | 4 | 2017 | 214052 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 1997 | 4262 | 0.010 |
Why?
|
Aged | 3 | 2017 | 163288 | 0.010 |
Why?
|
Killer Cells, Natural | 2 | 1999 | 2133 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 13882 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2504 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2004 | 1284 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2007 | 2765 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1999 | 25628 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2006 | 2700 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2016 | 21748 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2002 | 1865 | 0.010 |
Why?
|
Young Adult | 2 | 2017 | 56429 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2008 | 2417 | 0.010 |
Why?
|
Kidney | 1 | 2013 | 7184 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29060 | 0.010 |
Why?
|
Introns | 1 | 2000 | 992 | 0.010 |
Why?
|
CHO Cells | 1 | 2000 | 1409 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1997 | 242 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3799 | 0.010 |
Why?
|
Rats | 2 | 2006 | 24252 | 0.010 |
Why?
|
Galactosides | 1 | 1996 | 52 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 1 | 1996 | 118 | 0.010 |
Why?
|
Child | 2 | 2017 | 77709 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 85779 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14723 | 0.010 |
Why?
|
Sepharose | 1 | 1996 | 108 | 0.010 |
Why?
|
Cricetinae | 1 | 2000 | 2475 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 1997 | 534 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1996 | 356 | 0.010 |
Why?
|
Carbohydrate Sequence | 1 | 1996 | 414 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2000 | 2327 | 0.010 |
Why?
|
Tyrosine | 1 | 2000 | 1462 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2000 | 1730 | 0.010 |
Why?
|
Transforming Growth Factor alpha | 1 | 1995 | 135 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1996 | 1157 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2009 | 11031 | 0.010 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 1995 | 322 | 0.010 |
Why?
|
Lectins | 1 | 1996 | 513 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15535 | 0.010 |
Why?
|
Interleukin-1 | 1 | 1997 | 1263 | 0.010 |
Why?
|
Gene Transfer Techniques | 1 | 1999 | 1225 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 11726 | 0.010 |
Why?
|
Genetic Engineering | 1 | 1998 | 951 | 0.010 |
Why?
|
Spleen | 1 | 1998 | 2362 | 0.010 |
Why?
|
Triazoles | 1 | 1997 | 908 | 0.010 |
Why?
|
Molecular Structure | 1 | 1996 | 1899 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1996 | 3130 | 0.010 |
Why?
|
Interferon-gamma | 1 | 1997 | 3207 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 1996 | 2204 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2016 | 77460 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 2004 | 6364 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1995 | 4740 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1996 | 3759 | 0.000 |
Why?
|